Trazodone Side Effects: The Daytime Effects Patients Don't Realize Are Reportable

Most trazodone patients know about nausea, dry mouth, and the sedation that makes it useful as a sleep aid. Those are the easy-to-name effects. They come up at appointments because they are hard to ignore or because a prescriber asks about them by category.

The effects that rarely come up are the ones happening after sunrise: the grogginess that takes two hours to shake, the mild cognitive fog that makes complex tasks harder, the dizziness that happens when you stand up too quickly, the balance that felt slightly off. These are not dramatic. They do not announce themselves the way nausea does. And because they are subtle, many patients absorb them into their daily experience without connecting them back to the medication.

That connection matters clinically. Trazodone’s receptor profile, specifically its effects on histamine H1, alpha-1 adrenergic, and serotonin 5-HT2A receptors, does not switch off at bedtime. The drug’s half-life and the activity of its active metabolite mean that pharmacological effects can extend well into the following day, particularly at higher doses or in patients who metabolize the drug more slowly. The daytime effects are not incidental. They are a direct result of the same receptor interactions that make trazodone sedating at night.

What most patients do not realize is that these are reportable side effects. Reportable not just in the sense of “you can mention them,” but in the sense that they change clinical decisions: about dose, timing, formulation, or whether to continue the medication at all.

What Trazodone Is Actually Prescribed For

Trazodone was approved by the FDA in 1981 to treat major depressive disorder. That remains its only on-label indication. A 2025 study using nationally representative U.S. data estimated that approximately 24 million trazodone prescriptions were filled in 2019, with at least 85% written for off-label indications, primarily insomnia. Insomnia has become the dominant use case, far exceeding depression treatment.

The clinical rationale for trazodone’s sedative effects is its antagonism of H1 histamine receptors, alpha-1 adrenergic receptors, and 5-HT2A serotonin receptors at lower doses. The NIH StatPearls reference describes trazodone as an antidepressant that inhibits serotonin reuptake and blocks histamine and alpha-1 adrenergic receptors, and notes it is used off-label for insomnia despite insufficient clinical data to justify FDA approval for that indication.

The American Academy of Sleep Medicine’s clinical practice guidelines specifically state that physicians should not use trazodone as a first-line treatment for sleep-onset or sleep-maintenance insomnia. That recommendation exists in part because of the daytime effects described in this article.

Why Daytime Effects Go Unreported

There are several reasons patients do not bring up daytime trazodone effects at appointments. The most common: they attribute the effects to something else. Morning grogginess gets attributed to poor sleep quality, which was the original reason for taking trazodone. Cognitive fog gets attributed to depression, stress, or age. Dizziness when standing gets attributed to dehydration or skipping a meal. The medication is not the obvious candidate because the medication is associated with nighttime use.

A second reason is threshold. These effects are rarely dramatic enough to feel “worth mentioning.” If a patient’s pre-medication insomnia was severe, some morning grogginess can feel like a reasonable trade. The comparison is not medication versus no medication; it is medication-with-morning-grogginess versus no-sleep-at-all. That framing makes the side effect feel tolerable in a way that suppresses reporting.

The clinical cost of that suppression is real. A prescriber who does not know about daytime sedation cannot offer to adjust the timing of the dose, reduce the dose, or switch to a shorter-acting agent with lower next-day carryover. All of those options exist. They require the prescriber to know the problem exists first.

Morning Grogginess and Residual Sedation

Residual sedation is the technical term for the morning grogginess patients describe as feeling like climbing out of wet cement or taking two hours to feel like themselves. It is trazodone’s sedative action extending past the intended sleep period due to the drug’s half-life and the activity of its active metabolite, m-chlorophenylpiperazine (mCPP).

Clinical data confirms how common this is. A systematic review of trazodone for insomnia published in PMC identified daytime sleepiness as the most common adverse side effect of trazodone, along with headache and orthostatic hypotension. A 2024 comparative study of trazodone, doxepin, and melatonin in psychiatric patients found that 15% of the trazodone group reported morning grogginess, compared to 5% in the melatonin group, with the effect rated as statistically significant.

The clinical significance is that residual sedation impairs early-morning function in ways that matter: driving safety, reaction time, cognitive readiness for work, and the ability to care for dependents. Patients taking trazodone who have significant morning grogginess should report it because dose timing adjustments or dose reduction often reduce the effect substantially.

Cognitive and Memory Effects

The cognitive effects of trazodone have been studied directly. A double-blind, placebo-controlled crossover study by Roth, McCall, and Liguori enrolled 16 primary insomnia patients and found that 50mg trazodone administered nightly for seven days produced significant impairments in short-term memory, verbal learning, equilibrium, and arm muscle endurance compared to placebo. These effects were measured the morning after dosing on Days 1 and 7.

A broader systematic review of 16 studies on trazodone and human cognition found that acute trazodone use was associated with impaired cognitive function in several studies, with effects most pronounced when the drug was administered in the morning due to sedation impacting daily functioning, while long-term use showed either no effect or a possible protective association with cognitive decline.

Patients often do not report cognitive effects because they feel too diffuse to name. Difficulty finding words or staying focused in a meeting does not feel like a medication side effect. When these effects consistently follow trazodone doses, they are medication-related and worth reporting.

Dizziness When Standing (Orthostatic Hypotension)

Orthostatic hypotension is a drop in blood pressure when moving from lying or sitting to standing. It occurs because trazodone’s alpha-1 adrenergic receptor antagonism interferes with the blood vessel constriction response that normally maintains pressure when you change positions. The result is a brief drop in blood flow to the brain, producing dizziness, lightheadedness, or near-fainting.

A large retrospective Medicare cohort study of 1.7 million beneficiaries aged 65 or older found that trazodone was associated with significantly elevated fall risk compared to non-sleep-disordered controls, with fall rates of 9.5% for trazodone versus 7.7% for zolpidem immediate-release, attributed specifically to daytime drowsiness and orthostatic hypotension upon awakening.

Reporting orthostatic hypotension matters because it is manageable. Dose timing adjustments, hydration guidance, instruction on slow positional changes, and in some cases dose reduction all reduce the risk. The prescriber cannot deploy any of these without knowing the symptom is occurring.

Psychomotor Impairment and Falls Risk

Beyond orthostatic hypotension, trazodone produces a more general psychomotor impairment during the sedation window. In the Roth et al. study, equilibrium and muscle endurance were both significantly impaired the morning after trazodone dosing. These effects are particularly clinically significant in older adults.

The 2023 American Geriatrics Society Beers Criteria included trazodone as a potentially inappropriate medication in older adults due to concerns related to fall risk and confusion. Any reports of increased unsteadiness or near-falls following trazodone initiation or dose changes should be communicated to the prescriber immediately.

In younger patients, psychomotor effects are typically milder and dose-dependent. At lower doses used for sleep (25-100mg), the effects are less pronounced than at higher antidepressant doses (150-400mg). But less pronounced does not mean absent, and the effects are worth naming if they affect functioning.

What Makes These Side Effects Reportable

A side effect is reportable when it meets any of these criteria: it is affecting your daily functioning, it appeared or worsened after starting the medication or after a dose change, or it represents a safety risk such as driving or falls. Every daytime trazodone effect described in this article meets at least one of these criteria.

The more useful question to ask: did this symptom exist before I started trazodone, or before the dose was last changed? If the morning grogginess, the cognitive fog, the dizziness on standing, or the off-balance feeling appeared after medication initiation, the temporal relationship is clinically meaningful.

Systematic reviews confirm that the most common adverse effects leading to trazodone discontinuation are sedation, dizziness, and psychomotor impairment. These end treatment not because they cannot be managed, but because they were never reported until the patient stopped the medication on their own.

How Reporting Changes Your Treatment Options

Each of the daytime effects described here has a clinical management pathway once identified.

For morning grogginess and residual sedation: Taking trazodone earlier in the evening extends the time between peak sedation and waking. Dose reduction also reduces carryover sedation. For patients on higher doses for depression, dose splitting may reduce sedation peaks.

For cognitive effects: Timing adjustments often reduce the overlap between cognitive effects and functional morning hours. If cognitive effects persist beyond the first few weeks, a discussion about dose reduction, formulation change, or medication switch is warranted.

For orthostatic hypotension: Hydration before standing, slow positional changes, and seated pauses after waking reduce orthostatic symptoms. If insufficient, dose reduction or medication review may be warranted.

For psychomotor effects and falls risk: In older adults, the Beers Criteria specifically guides prescribers to weigh fall risk. A prescriber who knows about balance or coordination changes can assess whether the risk-benefit calculation supports continuing trazodone or exploring alternatives.

How SiggyMD Captures What Appointments Miss

The problem with daytime trazodone side effects is not that they are unmanageable. It is that the clinical window for reporting them, a 15-minute quarterly appointment, is too narrow to capture symptoms that patients normalize, attribute elsewhere, or do not connect to the medication they took hours earlier.

SiggyMD’s daily check-in design specifically addresses this gap. Medication timing, morning functioning, cognitive clarity, dizziness, and sleep quality are captured as standard components of the longitudinal clinical record. When a pattern of morning grogginess appears consistently the day after dosing, that pattern is visible in the data before the next clinical decision needs to be made.

“The side effects that change my recommendations most often are not the ones patients bring up unprompted,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “Trazodone is a medication that works for a lot of people, but the morning-after effects, including the cognitive carry-over and the blood pressure shift when they stand up, are real and addressable. When I have structured check-in data, I can make timing or dose adjustments earlier in the course of treatment, before the patient has already decided to stop the medication.”

What Members Are Saying

KR

K.R., 41

Depression with Insomnia

“I had been on trazodone for four months and the morning grogginess was significant, but I kept thinking it was just my depression. The daily check-in flagged it consistently and my prescriber connected it to the dosing time. Moving the dose earlier by two hours made a noticeable difference within a week.”

TP

T.P., 58

Major Depressive Disorder

“I was getting dizzy every morning when I stood up. I thought it was just getting older. When I logged it in the check-in, my prescriber said it was likely orthostatic hypotension from the trazodone and adjusted the dose. The dizziness stopped.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Bottom Line

Trazodone’s daytime effects are not rare, not imagined, and not simply the cost of treating insomnia or depression. They are documented clinical phenomena with specific mechanisms: residual H1 and alpha-1 receptor antagonism extending past the intended sleep window, producing morning grogginess, short-term cognitive impairment, orthostatic hypotension, and psychomotor changes that affect daily functioning.

What makes them different from the side effects that typically dominate clinical discussions is that they are subtle enough to be normalized. They happen in the context of conditions whose symptoms look similar, which makes attribution difficult. And they happen hours after the medication was taken, which breaks the obvious cause-and-effect connection.

These effects are reportable because they are manageable. Timing adjustments, dose reductions, and clinical monitoring can address all of them, but only if your prescriber knows they are occurring.

Sources

• Kadiyala S, Chenoweth M, Watanabe JH. Off-label policy through the lens of trazodone usage and spending in the United States. Health Affairs Scholar. 2025;3(7):qxaf114.

• Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. Journal of Sleep Research. 2011;20(4):552-558.

• Goncalo AM, Vieira-Coelho MA. The effects of trazodone on human cognition: a systematic review. European Journal of Clinical Pharmacology. 2021;77(11):1623-1637.

• Everitt H, et al. Trazodone for Insomnia: A Systematic Review. Innovations in Clinical Neuroscience. 2018;15(5-6):12-17.

• Psychopharmacology Institute. Trazodone Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects. Accessed May 2026.

• Mamoon B, Nawaz A, Khattak MI. Addressing Sleep Disorders in Psychiatry: Comparing the Use of Melatonin, Trazodone, and Doxepin. Cureus. 2024.

• La A, Walsh CM, Neylan TC, et al. Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers. Journal of Alzheimer’s Disease. 2019;67(3):911-921.

• U.S. National Library of Medicine. Trazodone. StatPearls. Accessed May 2026.

• American Geriatrics Society. 2023 American Geriatrics Society Beers Criteria Update. Journal of the American Geriatrics Society. 2023.